Mizuho Securities Sticks to Their Hold Rating for Nutrien (NTR)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rodriguez covers the Consumer Cyclical sector, focusing on stocks such as Ball, Crown Holdings, and Sealed Air. According to TipRanks, Rodriguez has an average return of 8.9% and a 63.24% success rate on recommended stocks.
In addition to Mizuho Securities, Nutrien also received a Hold from Jefferies's Laurence Alexander in a report issued on July 11. However, yesterday, RBC Capital maintained a Buy rating on Nutrien (NYSE: NTR).
NTR market cap is currently $29.71B and has a P/E ratio of 57.19.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NTR in relation to earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Why The Home Depot (HD) Remains a Reliable Dividend Pick in the Dogs of the Dow
The Home Depot, Inc. (NYSE:HD) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. An insurance broker discussing policy options with a homeowner. The company is facing challenges expanding its business amid a tough economic climate marked by elevated interest rates and growing caution among consumers when it comes to major purchases. Still, several positive trends could work in the company's favor. Housing inventory in the US remains tight compared to demand, and the average home is aging. In addition, homeowners have access to trillions of dollars in home equity that could be used for remodeling and improvements. As economic conditions stabilize or improve, Home Depot is likely to benefit from stronger demand. In the first quarter of 2025, The Home Depot, Inc. (NYSE:HD) reported revenue of $39.86 billion, up 9.44% from the same period last year. Comparable sales declined by 0.3%, while US comparable sales saw a slight increase of 0.2%. The company noted that fluctuations in foreign exchange rates had a negative effect, reducing overall comparable sales by about 70 basis points. The Home Depot, Inc. (NYSE:HD) reported an operating cash flow of $4.3 billion and ended the quarter with $1.4 billion in cash and cash equivalents. The company is a reliable dividend payer with 16 consecutive years of dividend growth under its belt. Currently, it offers a quarterly dividend of $2.30 per share for a dividend yield of 2.45%, as of July 26. While we acknowledge the potential of HD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
a few seconds ago
- Yahoo
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
a few seconds ago
- Yahoo
Johnson & Johnson's (JNJ) Defensive Strength Shines Among the Dogs of the Dow
Johnson & Johnson (NYSE:JNJ) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A smiling baby with an array of baby care products in the foreground. Johnson & Johnson (NYSE:JNJ) has a sizable and broadly positioned operation, with strong representation in both the medical devices and pharmaceutical sectors. Its leading status in the industry is also supported by its robust efforts in research and development, as well as effective marketing capabilities. In the second quarter of 2025, Johnson & Johnson (NYSE:JNJ) reported revenue of $23.7 billion, which showed a 5.77% growth from the same period last year. The company raised its full-year sales outlook by $2 billion to reflect a 5.4% increase, thanks to solid operational performance and positive foreign exchange impacts. It also boosted its earnings per share (EPS) forecast by $0.25, bringing it to $10.85. Meanwhile, adjusted operational EPS was revised to $10.68 at the midpoint. In its earnings report, Johnson & Johnson (NYSE:JNJ) indicated that its portfolio and pipeline have set the stage for accelerated growth in the latter half of the year. It expects significant approvals and regulatory submissions in key areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular health— advancements that are likely to enhance and extend lives in meaningful ways. Johnson & Johnson (NYSE:JNJ) is favored because of its strong dividend policy. The company has been growing its dividends for 63 consecutive years and currently pays a quarterly dividend of $1.30 per share. With a dividend yield of 3.09%, as of July 26, JNJ is among the best dogs of the Dow to invest in. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
